132 related articles for article (PubMed ID: 11389126)
21. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
Weiss K; Laverdiere M; Restieri C
J Antimicrob Chemother; 1998 Oct; 42(4):523-5. PubMed ID: 9818753
[TBL] [Abstract][Full Text] [Related]
22. Moxifloxacin (Avelox): an 8-methoxyquinolone antibacterial with enhanced potency.
Ball P
Int J Clin Pract; 2000 Jun; 54(5):329-32. PubMed ID: 10954961
[TBL] [Abstract][Full Text] [Related]
23. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
Dorai-John T; Thomson CJ; Amyes SG
J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
[TBL] [Abstract][Full Text] [Related]
24. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae.
Reinert RR; Schlaeger JJ; Lütticken R
J Antimicrob Chemother; 1998 Dec; 42(6):803-6. PubMed ID: 10052905
[TBL] [Abstract][Full Text] [Related]
25. Bactericidal activity of moxifloxacin against pneumococci.
Levy D; Berche P
Clin Microbiol Infect; 2001 Jan; 7(1):47-8. PubMed ID: 11284948
[No Abstract] [Full Text] [Related]
26. [Third and fourth generation fluoroquinolones].
Rossi C; Sternon J
Rev Med Brux; 2001 Oct; 22(5):443-56. PubMed ID: 11723788
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
28. New quinolones--a fresh answer to the pneumococcus.
Cubbon MD; Masterton RG
J Antimicrob Chemother; 2000 Dec; 46(6):869-72. PubMed ID: 11102402
[No Abstract] [Full Text] [Related]
29. [In vitro activity of moxifloxacin against respiratory pathogens in Latin America].
López H; Sader H; Amábile C; Pedreira W; Muñoz Bellido JL; García Rodríguez JA;
Rev Esp Quimioter; 2002 Dec; 15(4):325-34. PubMed ID: 12587037
[TBL] [Abstract][Full Text] [Related]
30. Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain.
Alós JI; Oteo J; Aracil B; Gómez-Garcés JL
J Antimicrob Chemother; 2001 Jul; 48(1):145-8. PubMed ID: 11418530
[No Abstract] [Full Text] [Related]
31. Activity of moxifloxacin against mycobacteria.
Gillespie SH; Billington O
J Antimicrob Chemother; 1999 Sep; 44(3):393-5. PubMed ID: 10511409
[TBL] [Abstract][Full Text] [Related]
32. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
[TBL] [Abstract][Full Text] [Related]
33. Antibacterial activity of AM-1155 against penicillin-resistant Streptococcus pneumoniae.
Tomizawa H; Tateda K; Miyazaki S; Yamaguchi K
J Antimicrob Chemother; 1998 Jan; 41(1):103-6. PubMed ID: 9511043
[TBL] [Abstract][Full Text] [Related]
34. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
Klugman KP; Capper T
J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
36. Experimental pneumococcal pleural empyema model: the effect of moxifloxacin.
Strahilevitz J; Lev A; Levi I; Fridman E; Rubinstein E
J Antimicrob Chemother; 2003 Mar; 51(3):665-9. PubMed ID: 12615869
[TBL] [Abstract][Full Text] [Related]
37. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
[TBL] [Abstract][Full Text] [Related]
38. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
Lister PD; Sanders CC
J Antimicrob Chemother; 2001 Jun; 47(6):811-8. PubMed ID: 11389113
[TBL] [Abstract][Full Text] [Related]
39. Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.
Rodriguez-Cerrato V; McCoig CC; Saavedra J; Barton T; Michelow IC; Hardy RD; Bowlware K; Iglehart J; Katz K; McCracken GH
Antimicrob Agents Chemother; 2003 Jan; 47(1):211-5. PubMed ID: 12499193
[TBL] [Abstract][Full Text] [Related]
40. Activity of grepafloxacin against respiratory isolates of Streptococcus pneumoniae.
Johnson AP; Warner M; Parsons T
Eur J Clin Microbiol Infect Dis; 1997 Aug; 16(8):622-3. PubMed ID: 9323481
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
